At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 26, 2026 at 07:30 ET
Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant and durable reductions in visceral fat (-14% vs. placebo) and improved body composition six months after a single dose. The results support advancement into Phase 2a trials in higher-BMI patients in 2Q 2026 and suggest potential in MASH, type 2 diabetes, and cardiovascular disease. The therapy continues to show a favorable safety profile.
- Single 240 mg dose of WVE-007 led to -14.3% placebo-adjusted reduction in visceral fat at 6 months (p<0.05)
- Total fat reduced by -5.3%, waist circumference by -3.3%, body weight by -0.9%, with lean mass preserved (+2.4%)
- Visceral fat-to-muscle ratio (VMR) improved by -16.5%, outperforming semaglutide's -12.2% in a higher-BMI population
- Serum Activin E suppressed up to 88%, supporting potential for once- or twice-yearly dosing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access